1S90
Seres Therapeutics, Inc., a clinical-stage company, focuses on developing biotherapeutics for serious diseases. The company develops SER-155, an investigational oral live biotherapeutic to decolonize gastrointestinal pathogens, enhance epithelial barrier integrity, and regulate immune response to prevent bacterial bloodstream infections, as well as other pathogen-associated negative clinical outc… Read more
1S90 (1S90) - Total Liabilities
Latest total liabilities as of September 2025: €99.78 Million EUR
Based on the latest financial reports, 1S90 (1S90) has total liabilities worth €99.78 Million EUR as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
1S90 - Total Liabilities Trend (2021–2024)
This chart illustrates how 1S90's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
1S90 Competitors by Total Liabilities
The table below lists competitors of 1S90 ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Amicogen Inc
KQ:092040
|
Korea | ₩139.22 Billion |
|
Birlesim Muhendislik Isitma Sogutma Havalandirma Sanayi & Ticaret Sirketi AS
IS:BRLSM
|
Turkey | TL3.74 Billion |
|
Auburn National Bancorporation Inc
NASDAQ:AUBN
|
USA | $-89.61 Million |
|
Centaur Media Plc
PINK:CAUUF
|
USA | $16.50 Million |
|
Lihtai Construction Enterprise Co Ltd
TWO:5520
|
Taiwan | NT$1.21 Billion |
|
Bangkok Aviation Fuel Services Public Company Limited
BK:BAFS
|
Thailand | ฿15.62 Billion |
Liability Composition Analysis (2021–2024)
This chart breaks down 1S90's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.30 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 2.28 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.70 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how 1S90's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for 1S90 (2021–2024)
The table below shows the annual total liabilities of 1S90 from 2021 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | €126.03 Million | -68.76% |
| 2023-12-31 | €403.46 Million | +19.37% |
| 2022-12-31 | €338.00 Million | +51.33% |
| 2021-12-31 | €223.35 Million | -- |